The Indian pharma industry is on the threshold of becoming a major global market by 2020. It is expected to grow at 15% to 20% CAGR to touch US$50 billion and US$74 billion in the next decade.
The country is a significant producer of APIs and formulations. Its pharma companies include global players in generics and vaccines. Some of the top Indian pharma companies are now partly foreign-owned and are already generating more than half of their sales outside the country.
India has a large pool of scientific manpower which can be used in drug discovery, development and clinical trials. Its diverse genetic pool of treatment-naive population is attractive for clinical trials.
Alongside, economic growth has increased the buying power of India’s middle class for healthcare services in general, particularly medicines. Emergence of lifestyle diseases such as diabetes, cardiovascular disease and cancer has increased the demand for medicines. Leading MNCs from Europe, the US and Japan have established a local presence.
We at PwC believe that no global pharmaceutical or life sciences company can afford to ignore India, either as a potential market, competitor or partner.
Globally, the industry is at the crossroads of many challenges and, at the same time, seeing new trends in technology that will help it break through some of the barriers that have previously held it back. Major scientific and technological advances, coupled with socio-demographic changes and increasing demand for medicines will revive the pharma industry’s fortunes in another 10 to 20 years.
The social, demographic and economic context in which the global pharmaceutical industry operates is changing. Developed economies with spiralling healthcare costs are looking to rein in healthcare expenditure. Payers are demanding a reimbursement model based on healthcare outcomes.